Chronische Nierenschwäche (Chronische Niereninsuffizienz) – Mikronährstofftherapie

Menschen mit chronischer Nierenschwäche gehören zu einer Risikogruppe, die anfälliger für einen Mangel folgender Vitalstoffe* ist:

• Vitamine: D [1], K [2] B1 [3], B6 [3], Folsäure [4]
• Mineralstoffe: Calcium [5, 33, 34], Kalium [4, 34-36]
• Spurenelemente: Eisen [4], Selen [6], Zink [4]

Im Rahmen der Mikronährstoffmedizin werden zur unterstützenden Therapie einer chronischen Nierenschwäche folgende Vitalstoffe* eingesetzt:

• Vitamine: Vitamin D [7, 8, 20, 21], Folsäure/Vitamin B6/B1 [27, 28]
• Spurenelemente: Eisen [29], Selen/Zink [30-32]
• Omega-3-Fettsäuren: Eicosapentaensäure (EPA), Docosahexaensäure (DHA) [9-16, 22-24]
• Sojaprotein [17, 25, 26]
• L-Carnitin und Coenzym Q10 [18, 19]

Detaillierte Informationen zu den einzelnen Mikronährstoffen finden Sie im DocMedicus Vitalstofflexikon.

Die obigen Vitalstoff-Empfehlungen wurden mithilfe des DocMedicus Expertensystems erstellt. Sämtliche Aussagen des Expertensystems sind durch Literatur mit hohen Evidenzgraden belegt.
Für eine Therapieempfehlung wurden nur klinische Studien mit den höchsten Evidenzgraden (Grad 1a/1b und 2a/2b) verwendet, die aufgrund ihrer hohen Aussagekraft die Therapieempfehlung belegen.

Hinweis!
Diese Daten werden in gewissen Zeitabständen aktualisiert.
Das DocMedicus Expertensystem ist stets auf dem aktuellen Stand der Vitalstoff-Forschung. Lassen Sie sich deshalb Ihre persönliche Vitalstoff-Analyse* mithilfe des DocMedicus Expertensystems bei Ihrem Arzt erstellen.

*Makronährstoffe (Kohlenhydrate, Fette, Proteine (Eiweiße)) und Mikronährstoffe (Vitamine, Mineralstoffe, Spurenelemente) sowie weitere Stoffe mit ernährungsspezifischer und physiologischer Wirkung

Vitalstoff-Analyse für den Mann

Vitalstoff-Analyse für die Frau

Männergesundheit – Vitalstoff-Analyse
Frauengesundheit – Vitalstoff-Analyse

Literatur

1. Dusso AS. Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl. 2003 Jun;(85):S6-9.
2. Bellone Federica, Cinquegrani Maria, Nicotera Ramona, Carullo Nazareno, Casarella Alessandro, Presta Pierangela, Andreucci Michele, Squadrito Giovanni, Mandraffino Giuseppe, Prunestì Marcello, Vocca Cristina, De Sarro Giovambattista, Bolignano Davide, Coppolino Giuseppe. Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health. Int J Mol Sci. 2022 Mai; 23, 9.
3. Bässler KH, Golly I, Loew D, Pietrzik K. Vitamin-Lexikon, 3. Auflage. Urban & Fischer, München, Jena (2002)
4. Biesalski HK: Vitamine, Spurenelemente und Minerale. Indikationen, Diagnostik, Therapie. 3. Auflage, Georg Thieme Verlag, München 2024
5. Bundesinstitut für Risikobewertung. Verwendung von Mineralstoffen in Lebensmitteln – Toxikologische und ernährungsphysiologische Aspekte. In: A Domke, R Großklaus, B Niemann, H Przyrembel, K Richter, E Schmidt, A Weißenborn, B Wörner, R Ziegenhagen: Verwendung von Mineralstoffen in Lebensmitteln – Toxikologische und ernährungsphysiologische Aspekte. BfR-Wissenschaft 04/2004, Berlin (2004)
6. Zachara Bronislaw A, Gromadzinska Jolanta, Palus Jadwiga, Zbrog Zbigniew, Swiech Rafal, Twardowska Ewa, Wasowicz Wojciech. The effect of selenium supplementation in the prevention of DNA damage in white blood cells of hemodialyzed patients: a pilot study. Biol Trace Elem Res. 2011 Sep; 142, 3: 274-83.
7. Lu R J, Zhu S M, Tang F L, Zhu X S, Fan Z D, Wang G L, Jiang Y F, Zhang Y. Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis. Eur J Clin Nutr. 2106 Feb; 71, 6: 683-693
8. Zheng Zhenfeng, Shi Huilan, Jia Junya, Li Dong, Lin Shan. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013 Sep; 14: 199
9. Hu Jing, Liu Zuoliang, Zhang Hao. Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics (Sao Paulo). 2017 Jan; 72, 1: 58-64
10. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a "very low dose" regimen. Ren Fail. 2004 Jul; 26(4):453-9.
11. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999 Oct; 10(10):2177-84.
12. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2009 Jan; 24(1):156-60. Epub 2008 Aug 6.
13. Hassan IR, Gronert K. Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J Immunol. 2009 Mar 1; 182(5):3223-32.
14. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Ren Nutr. 2007 Sep; 17(5):296-304.
15. Kim YJ, Chung HY. Antioxidative and anti-inflammatory actions of docosahexaenoic acid and eicosapentaenoic acid in renal epithelial cells and macrophages. J Med Food. 2007 Jun; 10(2):225-31.
16. Perunicic-Pekovic GB, Rasic ZR, Pljesa SI, Sobajic SS, Djuricic I, Maletic R, Ristic-Medic DK. Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton). 2007 Aug; 12(4):331-6.
17. Jing Zhou, Wei-Jie Yuan. Effects of soy protein containing isoflavones in patients with chronic kidney disease: A systematic review and meta-analysis. Clin Nutr. 2016 Feb; 35, 1: 117-24.
18. Ahmadi A, Begue G, Valencia AP, Norman JE, Lidgard B, Bennett BJ, Van Doren MP, Marcinek DJ, Fan S, Prince DK, Gamboa J, Himmelfarb J, de Boer IH, Kestenbaum BR, Roshanravan B. Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease. JCI Insight. 2023 Jun 8;8(11):e167274. doi: 10.1172/jci.insight.167274.
19. Sharma B, Yadav DK. L-Carnitine and Chronic Kidney Disease: A Comprehensive Review on Nutrition and Health Perspectives. J Pers Med. 2023 Feb 8;13(2):298. doi: 10.3390/jpm13020298.
20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001. Epub 2017 Jun 21. Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1. doi: 10.1016/j.kisu.2017.10.001.
21. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2011 Mar;6(3):482-8. doi: 10.2215/CJN.05310610.
22. Hu J, Liu Z, Zhang H. Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics (Sao Paulo). 2017 Jan 1;72(1):58-64. doi: 10.6061/clinics/2017(01)10.
23. Saglimbene VM, Wong G, van Zwieten A, Palmer SC, Ruospo M, Natale P, Campbell K, Teixeira-Pinto A, Craig JC, Strippoli GFM. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2020 Feb;39(2):358-368. doi: 10.1016/j.clnu.2019.02.041.
24. Chewcharat A, Chewcharat P, Rutirapong A, Papatheodorou S. The effects of omega-3 fatty acids on diabetic nephropathy: A meta-analysis of randomized controlled trials. PLoS One. 2020 Feb 11;15(2):e0228315. doi: 10.1371/journal.pone.0228315.
25. Zhang J, Liu J, Su J, Tian F. The effects of soy protein on chronic kidney disease: a meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2014 Sep;68(9):987-93. doi: 10.1038/ejcn.2014.112.
26. Azadbakht L, Shakerhosseini R, Atabak S, Jamshidian M, Mehrabi Y, Esmaill-Zadeh A. Beneficiary effect of dietary soy protein on lowering plasma levels of lipid and improving kidney function in type II diabetes with nephropathy. Eur J Clin Nutr. 2003 Oct;57(10):1292-4. doi: 10.1038/sj.ejcn.1601688.
27. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007 Sep 12;298(10):1163-70. doi: 10.1001/jama.298.10.1163.
28. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2011 Mar;6(3):482-8. doi: 10.2215/CJN.05310610.
29. Del Vecchio L, Cases A, Eisenga MF, Małyszko J, Barratt J, Bolignano D. KDIGO 2026 clinical practice guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2026 Jan 28:gfag014. doi: 10.1093/ndt/gfag014.
30. Elgenidy A, Amin MA, Awad AK, Husain-Syed F, Aly MG. Serum Zinc Levels in Chronic Kidney Disease Patients, Hemodialysis Patients, and Healthy Controls: Systematic Review and Meta-Analysis. J Ren Nutr. 2023 Jan;33(1):103-115. doi: 10.1053/j.jrn.2022.04.004.
31. Tokuyama A, Kanda E, Itano S, Kondo M, Wada Y, Kadoya H, Kidokoro K, Nagasu H, Sasaki T, Kashihara N. Effect of zinc deficiency on chronic kidney disease progression and effect modification by hypoalbuminemia. PLoS One. 2021 May 11;16(5):e0251554. doi: 10.1371/journal.pone.0251554.
32. Salehi M, Sohrabi Z, Ekramzadeh M, Fallahzadeh MK, Ayatollahi M, Geramizadeh B, Hassanzadeh J, Sagheb MM. Selenium supplementation improves the nutritional status of hemodialysis patients: a randomized, double-blind, placebo-controlled trial. Nephrol Dial Transplant. 2013 Mar;28(3):716-23. doi: 10.1093/ndt/gfs170.
33. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. doi: 10.1016/j.kisu.2017.04.001. Epub 2017 Jun 21. Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1. doi: 10.1016/j.kisu.2017.10.001.
34. Kim SM, Jung JY. Nutritional management in patients with chronic kidney disease. Korean J Intern Med. 2020 Nov;35(6):1279-1290. doi: 10.3904/kjim.2020.408.
35. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol. 2010 May;5(5):762-9. doi: 10.2215/CJN.05850809.
36. Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1050-60. doi: 10.2215/CJN.08580813.